详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Schuler, M.[1,2] ; Paz-Ares, L.[3,4] ; Sequist, L. V.[5,6] ; Tan, E. H.[7] ; Mok, T.[8] ; Hirsh, V.[9] ; O'Byrne, K.[10,11] ; Zhang, L.[12] ; Yamamoto, N.[13] ; Boyer, M.[14] ; Shah, R.[15] ; Bennouna, J.[16] ; Dickgreber, N. J.[17] ; De Greve, J.[18] ; Love, J.[19] ; Maerten, A.[20] ; Fan, J.[21] ; Ehrnrooth, E.[22] ; Park, K.[23] ; Yang, J. C. H.[24,25] ;

机构： [1]Univ Duisburg Essen, West German Canc Ctr, Univ Hosp Essen,Dept Med Oncol, Essen, Germany; [2]Partner Site Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany; [3]Hosp Univ Doce Octubre, Madrid, Spain; [4]CNIO, Med Oncol, Madrid, Spain; [5]Massachusetts Gen Hosp, Boston, MA 02114 USA; [6]Harvard Med Sch, Dept Thorac Oncol, Boston, MA USA; [7]Natl Canc Ctr, Div Med Oncol, Singapore, Singapore; [8]Chinese Univ Hong Kong, State Key Lab South China, Hong Kong Canc Inst, Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [9]McGill Univ, Med Oncol, Montreal, PQ, Canada; [10]Princess Alexandra Hosp, Brisbane, Qld, Australia; [11]Queensland Univ Technol, Canc Serv, Brisbane, Qld, Australia; [12]Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Med Oncol, Guangzhou, Guangdong, Peoples R China; [13]Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan; [14]Chris OBrien Lifehouse, Med Oncol, Camperdown, NSW, Australia; [15]Maidstone Hlth Author, Kent Oncol Ctr, Maidstone & Tunbridge Wells NHS Trust, Maidstone, Kent, England; [16]Inst Cancerol Ouest, Med Oncol, Nantes, France; [17]Mathias Spital Rheine, Thorac Oncol & Resp Care Med, Rheine, Germany; [18]UZ Brussels, Oncol Ctr, Med Oncol, Jette, Belgium; [19]Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA; [20]Boehringer Ingelheim Pharma GmbH & Co KG, TA Oncol, Ingelheim, Germany; [21]Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA; [22]Danmark AS, Boehringer Ingelheim, TA Oncol, Frederiksberg, Denmark; [23]Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Div Hematol Oncol, Seoul, South Korea; [24]Natl Taiwan Univ Hosp, Taipei, Taiwan; [25]Natl Taiwan Univ, Canc Ctr, Dept Oncol, Taipei, Taiwan

出处：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区

医学

小类 | 2 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 2 区肿瘤学

第一作者：

第一作者机构： [1]Univ Duisburg Essen, West German Canc Ctr, Univ Hosp Essen,Dept Med Oncol, Essen, Germany; [2]Partner Site Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany;

推荐引用方式(GB/T 7714)：

APA：

MLA：

First-line afatinib for advanced EGFR mutation-positive (EGFRm plus ) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials

文献详情